Biofrontera AG Operating Margin 2017-2021 | BFRA

Current and historical operating margin for Biofrontera AG (BFRA) over the last 10 years. The current operating profit margin for Biofrontera AG as of September 30, 2021 is -59.44%.
Biofrontera AG Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-09-30 $0.02B $-0.02B -84.21%
2021-03-31 $0.03B $-0.02B -71.43%
2020-09-30 $0.03B $-0.02B -74.07%
2020-03-31 $0.02B $-0.02B -87.50%
2019-03-31 $0.02B $-0.02B -85.00%
2018-09-30 $0.02B $-0.01B -62.50%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.112B $0.036B
Biofrontera AG is a biopharmaceutical company. It engaged in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases. The company's products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions which can sometimes lead to skin cancer as well as the treatment of certain forms of basal cell carcinoma in the European Union. Biofrontera AG is based in Leverkusen, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09